Lower anti-Müllerian hormone levels are associated with HIV in reproductive age women and shorter leukocyte telomere length among late reproductive age women
Clara E. Van Ommen, Arianne Y K Albert, Hélène C F Côté, Evelyn J Maan, Melanie C M Murray, Neora Pick, Jerilynn C Prior, Anthony Y.Y. Hsieh, Elana R. Kimmel, CIHR Team on Cellular Aging, HIV Comorbidities in Women, Children (CARMA-Endo; CIHR CTN 277)
We sought to better understand factors associated with ovarian aging in women with HIV (WWH).
Design
HIV has been associated with diminished fertility, younger age at menopause, and shorter leukocyte telomere length (LTL), a marker of cellular aging. We herein examine cross-sectional and longitudinal associations between LTL, anti-Müllerian hormone (AMH), and HIV.
Methods
We included WWH and HIV-negative women 12-50 years of age in the CARMA cohort with one or more study visit(s). LTL and AMH were measured by qPCR and ELISA, respectively. Women were analyzed in peak reproductive (<35 years) vs. late reproductive (≥35 years) life phases. Using multivariable mixed-effect linear or logistic regressions, we assessed factors associated with AMH and ΔAMH/year while adjusting for relevant confounders.
Results
WWH had shorter LTL and lower AMH levels compared to HIV-negative controls despite being of similar age. After adjusting for relevant factors, HIV was associated with 20% lower AMH levels in women under 35 years of age and shorter LTL was associated with AMH levels below 2 ng/ml among women aged 35 years or older. Longitudinally, ΔAMH/year was largely related to initial AMH level among older women, and to age in younger women.
Conclusions
Factors associated with AMH change across women's reproductive lifespan. Lower AMH among peak reproductive aged WWH suggests that HIV may have an initial detrimental effect on ovarian reserve, an observation that may warrant counseling around pregnancy planning. In women aged 35 years or older, the association between shorter LTL and lower AMH suggests that the immune and reproductive aging connections are more important in this age group.
anti-mullerian hormone HIV, ovarian aging HIV women, leukocyte telomere length ovarian reserve, ovarian reserve markers HIV, reproductive aging HIV infection, AMH diminished ovarian reserve, telomere length reproductive aging, HIV women ovarian function, late reproductive age HIV, biological aging ovarian reserve
PMID 36726239 36726239 DOI 10.1097/QAD.0000000000003481 10.1097/QAD.0000000000003481
Cite this article
Van Ommen, C. E., Hsieh, A. Y. Y., Albert, A. Y., Kimmel, E. R., Cote, H. C. F., Maan, E. J., Prior, J. C., Pick, N., Murray, M. C. M., CIHR Team on Cellular Aging, HIV Comorbidities in Women, & Children (CARMA-Endo; CIHR CTN 277) (2023). Lower anti-Müllerian hormone levels are associated with HIV in reproductive age women and shorter leukocyte telomere length among late reproductive age women. *AIDS (London, England)*, *37*(5), 769-778. https://doi.org/10.1097/QAD.0000000000003481
Van Ommen CE, Hsieh AYY, Albert AY, Kimmel ER, Cote HCF, Maan EJ, et al. Lower anti-Müllerian hormone levels are associated with HIV in reproductive age women and shorter leukocyte telomere length among late reproductive age women. AIDS. 2023;37(5):769-778. doi:10.1097/QAD.0000000000003481
Van Ommen, C. E., et al. "Lower anti-Müllerian hormone levels are associated with HIV in reproductive age women and shorter leukocyte telomere length among late reproductive age women." *AIDS (London, England)*, vol. 37, no. 5, 2023, pp. 769-778.
Serum progesterone (P) levels are critical for endometrial receptivity and implantation in frozen-thawed embryo transfer (FET) cycles. However, the prognostic role of P levels measured on the day of t...
STUDY QUESTION: Is there a difference in live birth rates at 24 months between infertile women with polycystic ovary syndrome (PCOS) who have normal versus abnormal glucose metabolism?
SUMMARY ANSWER...
PURPOSE: To evaluate the clinical relevance of serum progesterone levels on the day of frozen embryo transfer (FET) and the dose of vaginal progesterone gel (Crinone) used for early luteal phase suppo...
Brand KM et al., 2025Women's health (London, England)
Influential guidelines have supported the role of metformin in the management of polycystic ovary syndrome (PCOS) for a number of years. However, regulatory approvals for this therapeutic indication a...